Orly gears up for BTS season with new nail color collection
NEW YORK — Orly has unveiled Electronica, its new back-to-school nail color collection.
Inspired by the unique blend of nature and the machine, the result is high-tech style. The collection is available for $8.50 each on Orlybeauty.com, Sallybeauty.com and at Ulta Beauty stores.
The four lacquers in the Electronica collection include:
Preamp: Light purple shimmer;
Shockwave: Royal blue crème;
Decoded: Grey crème; and
Synchro: Duo chrome pink.
D.C. health department creates new pharmacy network for HIV drug-assistance program
WASHINGTON — All drugs provided to HIV and AIDS patients under the District of Columbia’s AIDS Drug Assistance Program will go through a new pharmacy network that includes Walgreens, the D.C. Department of Health said.
The department said it would shift the process of administering medications through CARE Pharmacies to administering them through agreements with individual pharmacies throughout the city. The transition started Monday and will continue through the end of August, and the department said it was in the process of inviting all registered pharmacies in the district to participate in the new network, which it said would be fully operational by Sept. 1.
As of Sunday, the network included 10 pharmacies: two Walgreens pharmacies, Super Pharmacy and Medical Equipment, Sterling Care Pharmacy, Seat Pleasant Pharmacy, Pharmacare @ DC, Morgan Pharmacy, H Street Care Pharmacy & Wellness Center, Apex Care Pharmacy and the AIDS Healthcare Foundation.
"The Department of Health has worked diligently with all relevant parties to ensure that this transition is seamless to patients in the AIDS Drug Assistance Program," D.C. Department of Health director Mohammad Akhter said. "We have done our research and look forward to being able to provide patients with increased access to services to allow them a more efficient treatment plan for their specific health needs. No client will lose access to their HIV medications because of this transition."
Study: Diabetes drugs may be associated with increased bladder cancer risk
NEW YORK — A drug commonly used to treat diabetes may be associated with an increased risk of bladder cancer, according to a new study published in the Canadian Medical Association Journal.
The researchers — who noted that Type 2 diabetics are at an increased risk of developing cancers, including a 40% increased risk of bladder cancer — conducted a systematic review and meta-analysis to evaluate the risk of bladder cancer among adults with Type 2 diabetes taking thiazolidinediones. The systematic review and meta-analysis of randomized controlled trials and observational studies involved more than 2.6 million patients. Among them, 3,643 had newly diagnosed bladder cancer.
"We observed an increased risk of bladder cancer associated with the use of thiazolidinediones," said Jeffrey Johnson of the School of Public Health at the University of Alberta. "In particular, use of pioglitazone was associated with an increased risk of bladder cancer based on a pooled estimate from three cohort studies involving more than 1.7 million individuals."
The researchers also looked at a possible association with rosiglitazone (another type of thiazolidinedione) but did not see an effect.
"Although the absolute risk of bladder cancer associated with pioglitazone was small, other evidence-based treatments for Type 2 diabetes may be equally effective and do not carry a risk of cancer," conclude the authors. "This study quantifies the association between pioglitazone use and bladder cancer and may help inform decisions around safer use of pioglitazone in individuals with Type 2 diabetes."